WO2010123558A1 - Système programmable de conditionnement de liquide cérébrospinal - Google Patents

Système programmable de conditionnement de liquide cérébrospinal Download PDF

Info

Publication number
WO2010123558A1
WO2010123558A1 PCT/US2010/001186 US2010001186W WO2010123558A1 WO 2010123558 A1 WO2010123558 A1 WO 2010123558A1 US 2010001186 W US2010001186 W US 2010001186W WO 2010123558 A1 WO2010123558 A1 WO 2010123558A1
Authority
WO
WIPO (PCT)
Prior art keywords
csf
pressure
controller
fluid
pump
Prior art date
Application number
PCT/US2010/001186
Other languages
English (en)
Inventor
Olin Palmer
Alex Butterwick
Thomas Saul
Richard Allen
Shivanand P. Lad
Original Assignee
Neurofluidics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurofluidics, Inc. filed Critical Neurofluidics, Inc.
Publication of WO2010123558A1 publication Critical patent/WO2010123558A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
    • A61M27/006—Cerebrospinal drainage; Accessories therefor, e.g. valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
    • A61M2027/004—Implant devices for drainage of body fluids from one part of the body to another with at least a part of the circuit outside the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/12—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit
    • A61M2205/125—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit with incorporated filters
    • A61M2205/126—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit with incorporated filters with incorporated membrane filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3331—Pressure; Flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0693—Brain, cerebrum

Definitions

  • the present invention relates generally to medical devices and methods. More specifically, the present invention relates to devices and methods for extracorporeal circulation, analysis, filtering and conditioning of cerebrospinal fluid (CSF).
  • CSF cerebrospinal fluid
  • Cerebrospinal fluid is a clear, watery fluid that surrounds the brain and spinal cord. It is produced in the human central nervous system (CNS) at a rate of about 0.3 ml/min in healthy adults. The total volume found in the ventricles and subarachnoid space is about 150ml at any moment. Thus the total volume is naturally replaced approximately 3 times a day. In normally functioning anatomy, the fluid naturally follows a circuit from production in the lateral ventricles, circulation over the surface of the brain and spinal cord and eventual drainage through the arachnoid granulations at the venous sinuses and lymphatic vessels.
  • the composition of the fluid can have a direct impact on the health of the brain with beneficial components in the fluid promoting brain health and pathogenic components having a deleterious effect on the brain.
  • pathology of a variety of compounds found within the CSF is increasingly understood, and it is believed that the elimination or treatment of these pathogens will lead to the prevention or amelioration of diseases such as Alzheimers, Parkinsons, Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Guillain Barre Syndrome as well as others.
  • the detection and removal, or at least reduction in concentration, of these compounds has been shown to have therapeutic effect.
  • the introduction of medicament into this fluid has also been shown to produce beneficial results.
  • the problem is compounded by the small diameter and long length of the extracorporeal circulation which causes "head loss" during flow, with pressures dynamically increasing in front of restrictions, and decreasing behind restrictions in the flow loop. Anticipating these artificial pressure artifacts and extrapolating the native pressures in the patient can be difficult.
  • the pressure in the extracorporeal circulation loop can change for a variety of other reasons such as restrictions (clogs, kinks, crushed tubing, closed valves, filter loading, etc), or changes in the patient's condition. (CSF leak, CSF overproduction, brain swelling, patient motion, etc).
  • each one of these references suffers from one or more of the following shortcomings: they rely on passive drainage of the CSF to the extracorporeal circulation loop which limits the drainage to the natural generation rate of the fluid in the CNS thereby limiting the amount of fluid that can be treated in a reasonable treatment session; they provide imprecise measurement of pressure in the circulation loop which exposes the patient to risk of excessive or insufficient CSF pressure in subarachnoid space with all the attendant risks already mentioned for that condition; they measure the pressure in the circulation loop at only one location so that they are not assured that the pressure at the point of drainage and reintroduction are equivalent thereby potentially creating undesirable intracranial pressure fluctuations in the subarachnoid space; the pressure monitoring alarm limits applied by the referenced systems do not take into account the shape of the pressure waveforms that exists in CSF pumping system so they must be set outside optimal limit levels to avoid false alarms caused by natural spikes and troughs in pressure waveforms thereby exposing the patient to unsafe pressure fluctuations or sub-optimal flow rates; the pressure sensing performed by
  • sensing and control system which does not sense pressure at drainage and reintroduction points, cannot distinguish between the native pressure of the CSF system and the pressure induced by the pumping system and cannot apply adaptive alarms to the pressure-wave forms thereby avoiding false alarm conditions. Furthermore the device must not suffer from the inability to synchronize the dispensing of medicament
  • the present disclosure advantageously addresses one or more of the aforementioned deficiencies in the field of CSF conditioning by providing a portable and 95 programmable CSF conditioning system that provides precise pressure monitoring and pumping control of the CSF through an extracorporeal fluid circuit as well as compositional analysis of pathogenic components of the fluid and dosing of medicament into the CSF in response to that analysis. It also provides turbulent reintroduction of the conditioned fluid into the subarachnoid space so that the conditioned fluid is more
  • the device is a closed loop extracorporeal fluid circuit for draining, pumping, controlling, analyzing and conditioning the flow of CSF for the purpose of treating brain injuries and disease.
  • the system designed to be worn by the patient in an in-patient or outpatient setting without connection to mobility impeding apparatus, actively pumps fluid
  • the drain and return points may be positioned in different CSF spaces, for example the drain may by attached in the lumbar thoracic CSF space while the return is in the subarachnoid CSF space.
  • One embodiment of the device comprises a specialized, multi-lumen catheter for
  • the lumens of the catheter are connected to a fluid circuit which guides the flow of the CSF outside the body.
  • other components such as pressure sensors for measuring the pressure at various locations along the circuit, devices for compositional analysis of
  • the fluid filter banks for removing targeted compounds from the CSF, medicament dispensers for dosing medicine into the fluid and pumps for controlling the flow of the CSF and for creating pressure waveforms in the flow.
  • the sensors, filters, pumps and dispensers are also electrically connected to a controller for synchronizing the operation of the various units in a manner that optimizes the CSF conditioning process with the first
  • the controller can toggle the pump between on and off duty cycle and can further synchronize the collection of
  • system may additionally measure the time constants of the transients in the pressure wave-forms following the pump starting or stopping (how long the system takes to reach steady state and the shape of the pressure build or decay curves). These time constants may provide diagnostic information for system configuration or performance. At the beginning of therapy, a time constant outside of
  • transmembrane pressure at the conditioning element too high, or pulsatility too low (note that measurement of pulsatility from patient breathing or cardiac cycle is normal, and the absence of that pulsatility may be interpreted as a possibly occluded flow path or other problem).
  • the alarms relevant to static pressures should only be triggered during static measurement, and the alarms relevant to dynamic
  • the measured pressures approaching an alarm condition may cause the system to adapt its operation, such as slowing down the flow if the transmembrane or patient return flow pressure is too high.
  • system measurements may include detection of the presence and concentration of deleterious or beneficial elements in the CSF.
  • the system may include one or more optical measurement flow cells which measure red blood cell concentration in the CSF, oxygen saturation level of the red blood cells, the concentration of free hemoglobin, etc. These data may be tracked and integrated with flow data to track total blood removed, changes in the condition of
  • the integrated measurement of total blood filtered from the CSF, trends in historical pressure measurements, or residence time of the cells on the filter membrane allow for prediction of required service interval for the CSF conditioning
  • system may incorporate the capability to deliver therapeutic agents to the CSF if certain alarm conditions are approached or met, such as delivering vasodilators if the conditions believed to trigger vasospasm are observed.
  • the system can include a capability for intentional use of
  • control algorithms which control the shape and timing of the pressure waveforms may vary so as to have a maximizing effect of the fluid
  • a gradually increasing and then comparatively more rapidly decreasing pressure may have a beneficial fluid exchange effect.
  • Other waveforms may also provide a therapeutic benefit as determined by further experimentation.
  • the timing of the pressure cycle can be so designed to take
  • the CSF is not circulated but is instead drained internally or externally to the body while at the same time artificial CSF is introduced through a separate line.
  • Pressure sensors are attached to the infusion line while
  • the infusion line may also be configured for the introduction of medicament, as in the preferred embodiment, although here it is introduced on a separate infusion line which also has a pressure wave unit
  • the measuring elements are pressure, compositional, etc.
  • control and pumping unit 215 collocated with the control and pumping unit while in others they may be remotely located from the control and pumping unit. For example attached to the extracorporeal fluid path, or embedded in the intraspinal catheter.
  • a novel and non obvious feature of the device and associated method is the 220 synchronization of the pressure measurement function with the pumping control and pressure waveform generation functions so that more precise pressure measurements can be made.
  • Another novel and non obvious feature of the device is the application of sophisticated process control apparatus to the system which provides for the 225 synchronization of the sensing, analysis and diagnostic functions with the pump duty cycle of the system in order to customize the treatment and therapeutic activities based on the feedback from transducers, compositional analysis sensors, and filters and the analysis of that feedback by the controller.
  • Another novel feature is the generation of pressure waveforms in the circulated 230 fluid in order to create turbulence at the fluid reintroduction point so there is more complete mixing of the fluid in the subarachnoid space, or in the bulk flow between the intracranial and intraspinal spaces if the drain and return points are positioned in a manner to promote flow through those regions.
  • Another novel feature is the feedback of the results of the compositional analysis 235 to the controller so that dosing of medicament is influenced by the composition of the fluid.
  • the device may afford the user one or more of the following advantages: a. enhanced pressure monitoring in both the drain and reintroduction flows by 240 applying an on/off duty cycle to the re-circulation and waveform pumps and then synchronizing the pressure sensing with that cycle so that measurements are recorded under both the static and dynamic conditions. This provides for enhanced precision of measurement of the patient's intracranial pressure (ICP), which is best measured under static conditions, and the transmembrane pressure of the filters, which is best measured 245 under dynamic conditions. Precise measurements of these two pressures are provided as feedback to the controller which responds with modulations to the pumping waveform and filter maintenance schedule which would not be available without this feature. b. integrated feedback of therapy effectiveness by examining trends in pathogen concentrations detected by sensors and using that information to analyze filter
  • FIG. 1 is a block diagram of the system and subsystems.
  • FIG. 2 is a schematic of the system showing relative positioning of the components of the system in the fluid circuit. 295
  • FIG. 3 is an illustration of the system connected to a patient.
  • FIG. 4A is a diagram of the pressure waveforms created by the pump duty cycle and the associated static alarm limits.
  • FIG. 4B is a diagram of the pressure waveforms created by the pump duty cycles and the associated adaptive alarm limits. 300
  • Cerebrospinal fluid is produced in the human central nervous system (CNS),
  • CSF is produced at a rate of about 0.3 ml/min and the total volume found in the ventricles and subarachnoid space is about 150ml at any moment.
  • 330 brain can also introduce elements into the CSF which impede the healing of the injury.
  • the device 10 is a closed loop extracorporeal fluid circuit 30 for draining, pumping, controlling, analyzing and conditioning the cerebrospinal fluid (CSF) for the purpose of treating brain injuries and disease and is designed to be worn by the patient
  • CSF cerebrospinal fluid
  • the device 10 comprises a multi-lumen catheter 20 for accessing the CSF in the subarachoid space 14, fluid drain 21 and fluid return lines 22, a plurality of pressure sensors 41, 42, 42, compositional analysis sensors 45, a filter bank 50, a circulation pump 65, a medicament dispenser 80, a pressure wave generating system with
  • the drain line 31 comprises standard medical attachment hardware, medical
  • the tubing is made of material which can be laterally flexed to accommodate positioning requirements but which limits volumetric expansion or contraction under pumping conditions.
  • Suitable materials used in simple monolithic or composite structures include typical cardiovascular and neurovascular catheter materials such as silicone, polyvinychloride, urethane and other
  • the pressure transducer 41 is positioned in the line 31 as close to the union with the catheter 20 as practical in order to avoid distortion of the signal by line loss or undesired perturbations in the system.
  • the transducer 41 has an inlet and outlet port for connection to the fluid circuit and will be connected through the
  • the device 10 further comprises compositional analysis sensors 45 which are designed to detect the presence and concentration of various constituent elements of the CSF including, but not limited to, the concentration of red blood cells, the oxygenated state of the blood, the concentration of free hemoglobin from lysed cells, and bilirubin.
  • the sensors 45 may comprise LED emitters capable of emitting discrete wavelengths of
  • compositional analysis sensors 45 can be arrayed sequentially or in parallel and may be situated as a stand-alone unit somewhere along the fluid circuit 30 or as an integrated
  • a filter bank 50 is positioned in the circuit 30 in order to removed target pathogens from the CSF which may contribute to diseases of the brain.
  • the filter bank 50 comprises a plurality of cartridges 55 containing disposable membranes, a purge mechanism and a filter transmembrane pressure transducer 42.
  • the cartridges 55 are hollow housings capable of removal or reinsertion. They are arrayed in parallel or series
  • the filter membranes are disposable hollow fiber membranes, or convoluted sheets with high surface area to volume ratios. The membranes are selected by pore size and capacity depending on the type of compound to be removed from the fluid.
  • Each parallel filter cartridge 55 is isolated from
  • the filter bank 50 further comprises a purge unit which is connected to each filter cartridge in order to back-flow or tangentially flow a fluid through the filter in the event the filter is clogged or needs to be cleaned.
  • the filter bank 50 further comprises a pressure transducer 42 in parallel with the filter cartridges 55 to measure transmembrane pressure and transmit that information via attached data grid
  • the device 10 further comprises a motorized circulation pump 65 connected to the fluid circuit 30 downstream from the filter bank 50 for the purpose of pumping the CSF from the subarachnoid space 14 through the extracorporeal circuit 30.
  • the pump is a motorized circulation pump 65 connected to the fluid circuit 30 downstream from the filter bank 50 for the purpose of pumping the CSF from the subarachnoid space 14 through the extracorporeal circuit 30.
  • the 415 65 comprises a housing, inlet's and outlets for connection to the circuit 30 and a mechanical pumping mechanism.
  • the pumping mechanism can be any type of commonly used mechanical pump such as a peristaltic roller, piston, bellows, pneumatic, screw mechanism or any other suitable means for creating vacuum or pressure in the range of +/- 200 mmHg.
  • the housing surrounding the moving pumping mechanism is in
  • the pump 65 is connected to a power supply via the power grid 127 and is connected to controller via the data grid 128 so that it may received signals for the purpose of controlling the pump's state. It is desirable that the pump 65 be located downstream from the filter bank 50 so that any blood cells in the
  • the system further comprises a medicament dispenser 80 attached to the fluid circuit 30.
  • the dispenser 80 comprises an electrically actuated isolation valve 82 connected to the fluid circuit 30, a reservoir 85 for holding medicament, and a pressure
  • the isolation valve 82 is an electrically powered valve and is connected to the power supply and the central processor and controller by power 127 and data grid 128. The valve 82 opens in response to signals sent from the controller 100 which controls the dispensing of medicament into the fluid stream while the pressure created by the pump 87 or pressure
  • the 435 cartridge 88 inject the medicament into the CSF circuit.
  • it may be a passive pressure valve that only opens upon injection of the therapeutic agent under pressure.
  • the medicament reservoir 75 comprises a chamber to hold fluid medicament with a port opening to the isolation valve 82 and a second port which exposes the chamber to the pressure source 87, 88.
  • the pressure source 87, 88 can be any pumping mechanism or
  • the medicament dispenser 80 may be positioned anywhere downstream of the filter bank 50 but preferably downstream of the re-circulation pump 65.
  • a pressure waveform generating unit 70 may also attached to the fluid circuit and
  • the 445 comprises a section of tubing 78, a motor driven pump 72 and a fluid reservoir 75.
  • the purpose of the unit 70 is to create pressure waveforms in the circulating CSF in order promote mixing of the CSF between the intracranial and intraspinal spaces, thereby improving the distribution of the conditioned CSF in those spaces.
  • the tubing 78 connects to the fluid circuit 30 and runs through the mixing pump 72 and into a reservoir
  • the pump 72 may be electrically powered and can be any of the kinds previously described for the circulation pump 65. It can be connected to the power supply 125 and controller 100 via the power 127 and data grid 128 respectively.
  • the reservoir 75 is in line with the pump 72 and may be positioned upstream or downstream of the pump in the wave generating unit 70. When activated, the pump 72 draws in CSF from the fluid
  • the pressure-wave generating unit 70 may be located anywhere in the circuit 30 downstream of the circulation pump 65.
  • the device 10 further comprises a return line 35 to transport the conditioned fluid from the pressure waveform generator 70 to the return lumen 25 of the catheter 20.
  • 460 return line 35 may contain a pressure transducer 43 to sense the actual pressure created by the combination of native pressure in the CSF from the patient, as well as the pressure created by the circulation pump 65 and the pressure waveform generator 70.
  • the transducer may be situated in the fluid circuit 30 as close as possible to the point where the CSF is re-introduced into the body, preferably just upstream of the union
  • the transducer is connected by the data grid 128 to the controller 100 and transmits signals to that unit which describe the actual waveform present in the circuit.
  • the device further comprises a controller 100 which controls the functionality of
  • the controller consists of a central processing unit (CPU)
  • the controller 100 is connected to the external input/output 112 which contains the user interface 115 and manufacturer's interface 118.
  • the user interface 115 displays information including but not limited to, instantaneous data from pressure transducers 41, 42, 43 and compositional analysis sensors 45, processed data such as flow rates and pressure waveforms, historical data such as filter life and volume of medicament
  • the user interface 115 also accepts inputs from the user including but not limited to, on/off commands, selection of pumping algorithms and waveforms, selection of medicament dispensing routines, and alarm conditions.
  • the manufacturer's interface 118 comprises an electrical interface compatible with standardized electrical cabling such as USB, Firewire, and RS232 ports to facilitate the loading of software and
  • the device 10 also comprises a power controller 125 and power supply 120.
  • the power supply 120 may be any AC or DC source but preferably a DC rechargeable supply. It provides power to the controller 100 and the electromechanical systems 12.
  • the device 10 also comprises an alarm unit 90 that can be triggered when limits
  • the alarms comprise audible alarm tones and visible message displays on the user interface 115.
  • alarms can be configured to trigger power relays in order to halt operations of the unit.
  • the power supply 120, and controller 100 as well as the compositional analysis sensors 45, filter bank 50, circulation pump 65, medicament dispenser 80 and pressure waveform generator 70 are all consolidated in a single, integrated console 60 that is wearable by the patient on a belt or other load-bearing device. In that case the only components not integrated into the console would be the
  • the CSF is not re-circulated but is instead drained internally or externally to the body while at the same time artificial CSF is introduced through a separate infusion line.
  • Pressure transducers 43 are attached to the infusion line while another pressure transducer 41 and compositional analysis sensors 45 are
  • the device 10 is used by attaching the CSF drain 21 and return 25 lines and their associated transducers 41, 43 to a specialty catheter 20 which has been inserted into the patient's spine and subarachnoid space in order to access the CSF.
  • the user inputs the parameters of a desired treatment regimen including but not limited to treatment time, pumping volume, dispensing volume
  • compositional analysis sensors 45 identify types and concentrations of pathogens or unwanted compounds in the blood and provide this information to the controller 100 which monitors the trends in concentration levels and responds by applying custom
  • medicament treatment routines that are indicated by the analysis of the patient's CSF.
  • stream filters 50 remove target pathogens from the CSF with the resulting decreasing concentration of the pathogens being confirmed by the optical sensors.
  • the medicaments dispensed by the dispenser 80 may provide therapy to the brain and can be dispensed under precisely monitored conditions whereby instantaneous and historical
  • the 545 data may be synthesized by the controller 100 so that the therapy regime is continuously updated based on feedback from the compositional analysis sensors 45 which indicate the changing concentrations of pathogens as a result of the filtering and treatment of the CSF.
  • the pressure waveform generator 70 further tailors the therapy by not only ensuring the medicament is mixed with the in-line CSF but also by promoting turbulence
  • the controller 100 analyzes the inputs from the pressure 41, 42, 43 and compositional analysis sensors 45 as well as historical data stored in the memory 105 and modifies operating algorithms and treatment regimens by changing pump duty cycles, sampling schemes and medicament dosages to customize the 555 treatment. In addition the controller 100 can apply adaptive alarms and usage alarms to ensure safety and maintenance limits are adhered to.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • External Artificial Organs (AREA)

Abstract

L'invention porte sur un système programmable (10) pour réguler la circulation extracorporelle et le conditionnement de liquide cérébrospinal pour le traitement de maladies cérébrales. Le système (10) comprend un circuit de liquide extracorporel (30) avec des capteurs de pression (41, 42, 43), des unités d'analyse de composition (45), des pompes (65, 72) et des distributeurs de médicament (80) ainsi qu'un dispositif de commande (100) qui synchronise les fonctions de détection, d'analyse et de conditionnement automatisées avec le fonctionnement du système de pompage (65, 72) de façon à augmenter la précision des mesures et à optimiser l'efficacité du traitement.
PCT/US2010/001186 2009-04-22 2010-04-21 Système programmable de conditionnement de liquide cérébrospinal WO2010123558A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17157709P 2009-04-22 2009-04-22
US61/171,577 2009-04-22

Publications (1)

Publication Number Publication Date
WO2010123558A1 true WO2010123558A1 (fr) 2010-10-28

Family

ID=43011391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/001186 WO2010123558A1 (fr) 2009-04-22 2010-04-21 Système programmable de conditionnement de liquide cérébrospinal

Country Status (1)

Country Link
WO (1) WO2010123558A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012033420A2 (fr) * 2010-09-10 2012-03-15 Telemetry Research Limited Cathéter et système de dérivation comprenant le cathéter
WO2017023419A1 (fr) * 2015-08-05 2017-02-09 Minnetronix, Inc. Système de filtration à flux tangentiel pour la filtration de matériaux provenant de fluides biologiques
WO2017096228A1 (fr) 2015-12-04 2017-06-08 Minnetronix, Inc. Systèmes et procédés pour le conditionnement du liquide céphalorachidien
US20170157374A1 (en) * 2006-10-09 2017-06-08 Minnetronix, Inc. Systems and methods for the conditioning of cerebrospinal fluid
US9895518B2 (en) 2006-10-09 2018-02-20 Neurofluidics, Inc. Cerebrospinal fluid purification system
WO2020010074A1 (fr) * 2018-07-02 2020-01-09 Minnetronix Neuro, Inc. Systèmes, cathéters et méthodes de traitement le long du système nerveux central
US10632237B2 (en) 2006-10-09 2020-04-28 Minnetronix, Inc. Tangential flow filter system for the filtration of materials from biologic fluids
US20200188646A1 (en) * 2015-10-06 2020-06-18 Minnetronix, Inc. Devices and methods for providing focal cooling to the brain and spinal cord
US10850235B2 (en) 2006-10-09 2020-12-01 Minnetronix, Inc. Method for filtering cerebrospinal fluid (CSF) including monitoring CSF flow
US11147540B2 (en) 2015-07-01 2021-10-19 Minnetronix, Inc. Introducer sheath and puncture tool for the introduction and placement of a catheter in tissue
US20210346588A1 (en) * 2020-05-11 2021-11-11 Minnetronix Neuro, Inc. Filtering cassettes and filtering systems
WO2022076598A1 (fr) * 2020-10-06 2022-04-14 Enclear Therapies, Inc. Système et procédé de commande d'écoulement de lcr et de gestion de pression intracrânienne
WO2023003888A1 (fr) * 2021-07-19 2023-01-26 Enclear Therapies, Inc. Plateforme de diagnostic du liquide céphalorachidien (lcr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032915A1 (en) * 2001-08-09 2003-02-13 Eunoe, Inc. System and method for treating elevated intracranial pressure
US20040068221A1 (en) * 1998-11-10 2004-04-08 Eunoe, Inc. Methods for the treatment of a normal pressure hydrocephalus
WO2008105959A2 (fr) * 2006-10-09 2008-09-04 Neurofluidics, Inc. Système de purification de fluide cérébrospinal

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040068221A1 (en) * 1998-11-10 2004-04-08 Eunoe, Inc. Methods for the treatment of a normal pressure hydrocephalus
US20030032915A1 (en) * 2001-08-09 2003-02-13 Eunoe, Inc. System and method for treating elevated intracranial pressure
WO2008105959A2 (fr) * 2006-10-09 2008-09-04 Neurofluidics, Inc. Système de purification de fluide cérébrospinal

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10398884B2 (en) 2006-10-09 2019-09-03 Neurofluidics, Inc. Cerebrospinal fluid purification system
US10850235B2 (en) 2006-10-09 2020-12-01 Minnetronix, Inc. Method for filtering cerebrospinal fluid (CSF) including monitoring CSF flow
US11065425B2 (en) 2006-10-09 2021-07-20 Neurofluidics, Inc. Cerebrospinal fluid purification system
US10695545B2 (en) 2006-10-09 2020-06-30 Minnetronix, Inc. Systems and methods for the conditioning of cerebrospinal fluid
US20170157374A1 (en) * 2006-10-09 2017-06-08 Minnetronix, Inc. Systems and methods for the conditioning of cerebrospinal fluid
US9895518B2 (en) 2006-10-09 2018-02-20 Neurofluidics, Inc. Cerebrospinal fluid purification system
US10632237B2 (en) 2006-10-09 2020-04-28 Minnetronix, Inc. Tangential flow filter system for the filtration of materials from biologic fluids
US20200046954A1 (en) 2006-10-09 2020-02-13 Neurofluidics, Inc. Cerebrospinal fluid purification system
US11529452B2 (en) 2006-10-09 2022-12-20 Minnetronix, Inc. Tangential flow filter system for the filtration of materials from biologic fluids
WO2012033420A2 (fr) * 2010-09-10 2012-03-15 Telemetry Research Limited Cathéter et système de dérivation comprenant le cathéter
WO2012033420A3 (fr) * 2010-09-10 2012-05-03 Telemetry Research Limited Cathéter et système de dérivation comprenant le cathéter
US11147540B2 (en) 2015-07-01 2021-10-19 Minnetronix, Inc. Introducer sheath and puncture tool for the introduction and placement of a catheter in tissue
CN108367102B (zh) * 2015-08-05 2021-04-30 米奈特朗尼克斯有限公司 用于来自生物流体的物料的过滤的切向流过滤器系统
JP7166915B2 (ja) 2015-08-05 2022-11-08 ミネトロニクス， インコーポレイテッド 体液から物質を濾過する為の接線流フィルターシステム
JP6995916B2 (ja) 2015-08-05 2022-01-17 ミネトロニクス， インコーポレイテッド 体液から物質を濾過する為の接線流フィルターシステム
JP2018523524A (ja) * 2015-08-05 2018-08-23 ミネトロニクス， インコーポレイテッド 体液から物質を濾過する為の接線流フィルターシステム
CN108367102A (zh) * 2015-08-05 2018-08-03 米奈特朗尼克斯有限公司 用于来自生物流体的物料的过滤的切向流过滤器系统
AU2021218067B2 (en) * 2015-08-05 2023-03-16 Minnetronix, Inc. Tangential flow filter system for the filtration of materials from biologic fluids
JP2020124526A (ja) * 2015-08-05 2020-08-20 ミネトロニクス， インコーポレイテッド 体液から物質を濾過する為の接線流フィルターシステム
WO2017023419A1 (fr) * 2015-08-05 2017-02-09 Minnetronix, Inc. Système de filtration à flux tangentiel pour la filtration de matériaux provenant de fluides biologiques
US20200188646A1 (en) * 2015-10-06 2020-06-18 Minnetronix, Inc. Devices and methods for providing focal cooling to the brain and spinal cord
AU2016364907B2 (en) * 2015-12-04 2019-08-22 Minnetronix, Inc. Systems and methods for the conditioning of cerebrospinal fluid
JP2018537191A (ja) * 2015-12-04 2018-12-20 ミネトロニクス， インコーポレイテッド 脳脊髄液を処置するためのシステム
EP4238593A1 (fr) * 2015-12-04 2023-09-06 Minnetronix Inc. Systèmes de conditionnement de liquide cérébrospinal
EP3842080A1 (fr) * 2015-12-04 2021-06-30 Minnetronix Inc. Systèmes de conditionnement de liquide cérébrospinal
AU2019268213B2 (en) * 2015-12-04 2020-10-22 Minnetronix, Inc. Systems and methods for the conditioning of cerebrospinal fluid
JP2020096857A (ja) * 2015-12-04 2020-06-25 ミネトロニクス， インコーポレイテッド 脳脊髄液の状態調整のためのシステム及び方法
CN108778355B (zh) * 2015-12-04 2021-04-30 米奈特朗尼克斯有限公司 用于对脑脊液进行调节的系统及方法
WO2017096228A1 (fr) 2015-12-04 2017-06-08 Minnetronix, Inc. Systèmes et procédés pour le conditionnement du liquide céphalorachidien
US11577060B2 (en) 2015-12-04 2023-02-14 Minnetronix, Inc. Systems and methods for the conditioning of cerebrospinal fluid
CN108778355A (zh) * 2015-12-04 2018-11-09 米奈特朗尼克斯有限公司 用于对脑脊液进行调节的系统及方法
CN112654387B (zh) * 2018-07-02 2023-08-15 米奈特朗尼克斯神经有限公司 用于沿中枢神经系统进行治疗的系统、导管和方法
AU2019298242B2 (en) * 2018-07-02 2022-09-15 Minnetronix Neuro, Inc. Systems, catheters, and methods for treating along the central nervous system
WO2020010074A1 (fr) * 2018-07-02 2020-01-09 Minnetronix Neuro, Inc. Systèmes, cathéters et méthodes de traitement le long du système nerveux central
CN112654387A (zh) * 2018-07-02 2021-04-13 米奈特朗尼克斯神经有限公司 用于沿中枢神经系统进行治疗的系统、导管和方法
AU2022283781B2 (en) * 2018-07-02 2024-02-22 Minnetronix Neuro, Inc. Systems, catheters, and methods for treating along the central nervous system
US11992637B2 (en) 2018-07-02 2024-05-28 Minnetronix Neuro, Inc. Systems, catheters, and methods for treating along the central nervous system
WO2021231311A1 (fr) * 2020-05-11 2021-11-18 Minnetronix Neuro, Inc. Cassettes de filtration et systèmes de filtration
US20210346588A1 (en) * 2020-05-11 2021-11-11 Minnetronix Neuro, Inc. Filtering cassettes and filtering systems
JP7536890B2 (ja) 2020-05-11 2024-08-20 ミネトロニクス ニューロ インコーポレイテッド 濾過カセット及び濾過システム
WO2022076598A1 (fr) * 2020-10-06 2022-04-14 Enclear Therapies, Inc. Système et procédé de commande d'écoulement de lcr et de gestion de pression intracrânienne
WO2023003888A1 (fr) * 2021-07-19 2023-01-26 Enclear Therapies, Inc. Plateforme de diagnostic du liquide céphalorachidien (lcr)

Similar Documents

Publication Publication Date Title
WO2010123558A1 (fr) Système programmable de conditionnement de liquide cérébrospinal
EP1543852B1 (fr) Appareil pour le traitement du sang
JP7073103B2 (ja) 人工脳脊髄液の治療応用及びそのためのツール
EP2519275B1 (fr) Détection de dégradation d'écoulement sanguin
EP3233152B1 (fr) Système et procédé de dialyse péritonéale
US7842002B2 (en) Device for the extravascular recirculation of liquid in body cavities
EP2883557B1 (fr) Système de traitement sanguin extracorporel pour traitement individualisé
EP3281655B1 (fr) Retrait de fluide de dialyse péritonéale adaptatif intersession pour optimisation de sessions multiples
CN101252958A (zh) 流体交换导管系统
JP2020509918A (ja) 体液交換システムおよび関連する方法
JP2001511679A (ja) 血液濾過システム
JP2021008490A (ja) 人工脳脊髄液の治療応用及びそのためのツール
CA3000747C (fr) Dispositifs et procedes pour apporter un refroidissement local au cerveau et a la moelle epiniere
US9233237B2 (en) Apparatus and method for periodic fluid-delivery/fluid-removal cycles in the cranial subarachnoid space to treat cerebral cortical disorders
JP2021532936A (ja) 中枢神経系に沿って治療するためのシステム、カテーテル、および方法
JP2023546358A (ja) Ｃｓｆフローを制御し、頭蓋内圧を管理するためのシステムおよび方法
CN204275134U (zh) 血液稀释、清洁治疗仪
JPH0686810A (ja) 血液浄化装置
US11883529B2 (en) Methods of administering anti-epilepsy agents and transport inhibitors to a subject
US11654260B1 (en) Ultrasound-placed pain management system and method with subcutaneous catheter
US20230355118A1 (en) System and method for monitoring physiological parameters based on cerebrospinal fluid pressures taken at two or more locations
Gribbons et al. Failure Modes and Effects Analysis: Off-Label Use of Alaris Infusion Pump for Cerebrospinal Fluid Subarachnoid Drainage
CN118512675A (zh) 一种智能控制的血液透析用自动止液输液器
IT202100028082A1 (it) Apparatus for extracorporeal blood treatment
RU2414249C1 (ru) Аппарат для двухигольного плазмафереза

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10767423

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10767423

Country of ref document: EP

Kind code of ref document: A1